jueves, 29 de enero de 2015

NLM Director’s Comments Transcript - Aspirin: Initial Heart Attack and Stroke

NLM Director’s Comments Transcript - Aspirin: Initial Heart Attack and Stroke

A service of the U.S. National Library of Medicine
From the National Institutes of HealthNational Institutes of Health

Picture of Dr. Lindberg

NLM Director’s Comments Transcript
Aspirin: Initial Heart Attack and Stroke: 01/26/2015

Aspiring and heart disease poster with portrait of a senior.

Greetings from the National Library of Medicine and MedlinePlus.gov
Regards to all our listeners!
I'm Rob Logan, Ph.D. senior staff U.S. National Library of Medicine for Donald Lindberg, M.D, the Director of the U.S. National Library of Medicine.
Here is what's new this week in MedlinePlus.listen
A daily, low dose aspirin may not prevent heart attacks, strokes as well as some other heart disease related conditions for older adults, suggests a comprehensive Japanese study and an accompanying editorial recently published in theJournal of the American Medical Association.
A randomized clinical trial of 14,464 patients who participated in the Japanese Primary Prevention Project (JPPP) compared adults age 60 or older (who randomly received one daily, low dose aspirin) to a group that did not take aspirin. Although none of the study’s participants had a prior heart attack or stroke, all were diagnosed with high blood pressure, diabetes, or high fat/cholesterol levels in their blood. The study’s authors noted the latter conditions increased the risks of a heart attack and a stroke for all participants.
The study’s 11 authors explain prior to this research, all the study’s participants might have been considered candidates for a low dose aspirin in order to prevent stroke, heart attacks, and related cardiovascular events from initially occurring.
However, the Japanese researchers stopped the study (which was expected to last for six and half years) in its fifth year because no statistically significant differences in non-fatal heart attacks and other related conditions were reported between the two groups.
After five years, the study’s authors reported 20 participants who received aspirin experienced a nonfatal heart attack compared to 38 persons who did not receive aspirin.
Similarly, the study found no significant differences in preventing nonfatal strokes and fatal cardiovascular events between the aspirin and non-aspirin groups. Overall, about 2.7 percent of the participants who took daily low dose aspirin had a heart attack, stroke, or other heart disease-related event compared to 2.9 percent among those who did not take aspirin.
The two authors of an editorial that accompanied the study write (and we quote): ‘The JPPP study adds to the body of evidence that helps refine the answer to the question of when aspirin should be used to prevent vascular events’ (end of quote).
However, the editorial’s authors (who include JAMA’s senior editor) conclude the study suggests (and we quote) ‘patients at very low risks of vascular events should not take aspirin for prevention of vascular events, even at low dose’ (end of quote).
The editorial’s authors note the study’s overall findings fail to challenge or counter existing research that suggests aspirin helps prevent against a second heart attack, stroke, or other cardiovascular illnesses -- or aspirin is therapeutic for adults at a high immediate risk of a heart attack or stroke.  The editorial’s authors write (and we quote): ‘aspirin is indicated for patients at high-short-term risk due to an acute vascular event and those undergoing certain vascular procedures; patients with any evidence of vascular disease should be given daily aspirin’ (end of quote).
Ironically, the editorial’s authors explain after a century of use, the evidence about aspirin’s optimal use is still emerging. They write (and we quote): ‘the balance between benefit in preventing major vascular events and the risk of increasing serious bleeding…underlies the clinical decision of when to use this inexpensive generic drug’ (end of quote).
Meanwhile, MedlinePlus.gov’s heart attack health topic page provides links to two websites that provide insights into taking aspirin to prevent initial or repeated heart disease and stroke. A website from the U.S. Food and Drug Administration (available in MedlinePlus.gov’s heart attack health topic page’s  ‘prevention/screening’ section) provides basic information about taking aspirin to reduce the risk of heart attack, heart conditions, and stroke.
A website from the U.S. Office of Disease Prevention and Health Promotion (also available in the ‘prevention/screening’ section of MedlinePlus.gov’s heart attack health topic page) adds tips on talking to a physician about taking aspirin daily. 
MedlinePlus.gov’s heart attack health topic page additionally provides links to the latest pertinent journal research articles, which are available in the ‘journal articles’ section. Links to clinical trials that may be occurring in your area are available in the ‘clinical trials’ section. You can sign up to receive updates about heart attacks as they become available on MedlinePlus.gov.
To find MedlinePlus.gov’s heart attack health topic page, type ‘heart attack’ in the search box on MedlinePlus.gov’s home page, then, click on ‘Heart attack (National Library of Medicine).’ MedlinePlus.gov also has health topic pages devoted to heart disease and vascular (or blood system) diseases. There is specific information about aspirin’s safety within the ‘drugs & supplements’ section, which is accessible on MedlinePlus.gov’s home page.
Before I go, this reminder… MedlinePlus.gov is authoritative. It's free. We do not accept advertising …and is written to help you.
To find MedlinePlus.gov, just type ‘MedlinePlus.gov’ in any web browser, such as Firefox, Safari, Chrome, or Explorer.  To find the improved smartphone version of Mobile MedlinePlus.gov, just type ‘Mobile MedlinePlus’ in the same web browsers.
We encourage you to use MedlinePlus and please recommend it to your friends. MedlinePlus is available in English and Spanish. Some medical information is available in 43 other languages.
Your comments about this or any of our podcasts are always welcome. We welcome suggestions about future topics too!
Please email Dr. Lindberg anytime at: NLMDirector@nlm.nih.gov
That's NLMDirector (one word) @nlm.nih.gov
A written transcript of recent podcasts is available by typing 'Director's comments' in the search box on MedlinePlus.gov's home page.
The National Library of Medicine is one of 27 institutes and centers within the National Institutes of Health. The National Institutes of Health is part of the U.S. Department of Health and Human Services.
A disclaimer — the information presented in this program should not replace the medical advice of your physician. You should not use this information to diagnose or treat any disease without first consulting with your physician or other health care provider.
I want to take the opportunity to wish you a very happy holiday season and a healthy New Year. The National Library of Medicine and the ‘Director’s Comments’ podcast staff, including Dr. Lindberg, appreciate your interest and company — and we hope to find new ways to serve you in 2015.

No hay comentarios:

Publicar un comentario